Breaking:CSIR Develops New Process Technology For Favipiravir
CSIR transfers Cost Effective Process Technology of Favipiravir to CIPLA
Positive India:New Delhi;24July 20:
Its a breaking news as CSIR has developed New Process Technology For Favipiravir and transferred the same to Cipla for manufacturing this cost effective COVID-19 drugs on mass scale.
An off patent anti-viral drug Favipiravir, originally discovered by Fuji, Japan has shown promise in clinical trials for treatment of Covid-19 patients, especially the mild and the moderate patients.
CSIR constituent lab CSIR-Indian Institute of Chemical Technology (CSIR-IICT) has developed a cost effective process using locally available chemicals to synthesize this Active Pharmaceutical Ingredient (API) and transferred the Favipiravir Process Technology to leading pharmaceutical industry M/s Cipla Limited.
Cipla has scaled up the process in their manufacturing facility and approached DCGI for permission to launch the product in India. Given that DCGI has given restricted emergency use for Favipiravir in the country, Cipla is now all set to launch the product to help patients suffering from Covid-19.
Commenting on the development, Director CSIR-IICR, Dr.S. Chandrashekhar said that the technology provided by CSIR-IICT is very efficient and makes it affordable and allows Cipla to make large quantities of the product within a short span of time.
DG-CSIR, Dr Shekhar C Mande observed that CSIR is working with industry in developing quick solutions and products for mitigation of Covid-19 and this partnership with Cipla is an example of how CSIR is committed in bringing repurposed drugs on a fast track.
